3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Specimen Handling
5
Carboplatin
4
X-Rays
3
Rituximab
3
Prednisone
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Abiraterone Acetate
3
trastuzumab deruxtecan
2
talquetamab
2
pertuzumab
2
pembrolizumab
2
olaparib
2
niraparib
2
erdafitinib
2
durvalumab
2
belzutifan
2
apalutamide
2
acalabrutinib
2
Trastuzumab
2
Sunitinib
2
Phantoms, Imaging
2
Paclitaxel
2
Immunoglobulin G
2
Disulfides
2
Dexamethasone
2
Dasatinib
2
Cyclophosphamide
2
Crizotinib
2
CT-P10
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
entrectinib
×
30 days
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA